07.30.24 -- Regulatory T Cells And Autoimmune Disease

Watch as speakers share a variety of challenges encountered when closing and automating ancillary processes, and how closed automated platforms improved scalability and reproducibility.

Delve into the world of epilepsy, exploring its prevalence, ongoing trials, drugs in development, and ultimately, how these advancements can improve the lives of people living with seizures.

During this panel, experts discuss the challenges faced by developers and manufacturers in the immune cell therapy field. These challenges include scalability, regulatory hurdles, and data standardization.

From tumor resection to therapy delivery, there are a number of hurdles at each stage of your TIL therapy manufacturing workflow. Here, we address key challenges at each stage of the workflow.

Those outside document management often don't see themselves as stakeholders. Even after general TMF training, they may not fully understand their role within the TMF.

Unlock the potential of patient-centric solutions by striking the right balance between innovation and practicality in trial design. Discover how to optimize recruitment, retention, and outcomes.

Vaccines have a rich history of safeguarding populations against diseases. Discover how with advanced vaccine technologies, researchers can create safer and more effective vaccines.

By exploring innovative approaches to scaling up animal cell growth in cutting-edge bioreactor systems, foodtech companies are poised to offer healthier, safer, more sustainable fish for consumers.

Compare the use of a cGMP, xeno-free media supplement to human serum as a supplement for T cell growth in cell therapy development.

With this family of products demonstrating high yield and viability rates while maintaining target NTU readings, teams can better clarify HEK293 cells in various stages of production.

The industry is shifting from traditional processes to taking advantage of single-use technology benefits. Learn how to bypass traditional biomanufacturing and disposable multilayered films.

The rapid rise of highly targeted cell and gene treatments requiring small batch production necessitates a new path forward for biologics manufacturing and directly impacts the CMO/CDMO landscape.